IL260750B2 - Clinical evaluation of protein-M response in multiple myeloma - Google Patents

Clinical evaluation of protein-M response in multiple myeloma

Info

Publication number
IL260750B2
IL260750B2 IL260750A IL26075018A IL260750B2 IL 260750 B2 IL260750 B2 IL 260750B2 IL 260750 A IL260750 A IL 260750A IL 26075018 A IL26075018 A IL 26075018A IL 260750 B2 IL260750 B2 IL 260750B2
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
albumin
idiotypic antibody
Prior art date
Application number
IL260750A
Other languages
English (en)
Hebrew (he)
Other versions
IL260750B1 (en
IL260750A (https=
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of IL260750A publication Critical patent/IL260750A/en
Publication of IL260750B1 publication Critical patent/IL260750B1/en
Publication of IL260750B2 publication Critical patent/IL260750B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
IL260750A 2016-03-04 2017-03-03 Clinical evaluation of protein-M response in multiple myeloma IL260750B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158714 2016-03-04
PCT/EP2017/055011 WO2017149122A1 (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Publications (3)

Publication Number Publication Date
IL260750A IL260750A (https=) 2018-09-20
IL260750B1 IL260750B1 (en) 2023-10-01
IL260750B2 true IL260750B2 (en) 2024-02-01

Family

ID=55745535

Family Applications (2)

Application Number Title Priority Date Filing Date
IL260750A IL260750B2 (en) 2016-03-04 2017-03-03 Clinical evaluation of protein-M response in multiple myeloma
IL305540A IL305540B2 (en) 2016-03-04 2017-03-03 Clinical evaluation of protein-M response in multiple myeloma

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL305540A IL305540B2 (en) 2016-03-04 2017-03-03 Clinical evaluation of protein-M response in multiple myeloma

Country Status (9)

Country Link
US (3) US11618789B2 (https=)
EP (1) EP3423498A1 (https=)
JP (4) JP7362250B2 (https=)
KR (1) KR102427948B1 (https=)
CN (1) CN108699161B (https=)
AU (2) AU2017226960B2 (https=)
IL (2) IL260750B2 (https=)
SG (1) SG11201806214RA (https=)
WO (1) WO2017149122A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209730A1 (en) 2018-04-24 2019-10-31 Helena Laboratories Corporation Removal of interfering factors from serum protein electrophoresis profiles
AU2019338999A1 (en) 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
JP7687956B2 (ja) 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
WO2023094696A1 (en) * 2021-11-29 2023-06-01 Morphosys Ag Methods for reducing anti-cd38 mab drug interference in serological assays

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
US20090130089A9 (en) * 2006-10-10 2009-05-21 Vaccinex, Inc. Anti-cd20 antibodies and methods of use
US20130302318A1 (en) * 2010-09-27 2013-11-14 Lisa Rojkjaer Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912610A (en) * 1974-07-23 1975-10-14 Icl Scient Method for electroquantitative determination of proteins
US4102990A (en) * 1977-12-05 1978-07-25 General Electric Company Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling
US4661586A (en) 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4578350A (en) * 1983-09-23 1986-03-25 Syntex (U.S.A.) Inc. Immunoassays employing protected labels
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US6902669B2 (en) 2002-09-13 2005-06-07 Fleetguard, Inc. Filter cartridge with floating seal
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2007146038A2 (en) * 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20110151494A1 (en) * 2008-06-30 2011-06-23 H. Lee Moffit Cancer & Research Institute Methods and materials for monitoring myeloma using quantitative mass spectrometry
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
JP2014504850A (ja) 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL2831237T3 (pl) 2012-03-30 2018-06-29 The Board Of Regents Of The University Of Oklahoma Polimery heparosanu o wysokiej masie cząsteczkowej i sposoby ich wytwarzania i zastosowania
MX368288B (es) 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
BR112015027313A2 (pt) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
WO2015121454A1 (en) 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
US20090130089A9 (en) * 2006-10-10 2009-05-21 Vaccinex, Inc. Anti-cd20 antibodies and methods of use
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
US20130302318A1 (en) * 2010-09-27 2013-11-14 Lisa Rojkjaer Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
[XI] - YAZAKI ET AL,, BIODISTRIBUTION AND TUMOR IMAGING OF AN ANTI-CEA SINGLE-CHAIN ANTIBODY-ALBUMIN FUSION PROTEIN, 28 February 2008 (2008-02-28) *

Also Published As

Publication number Publication date
IL260750B1 (en) 2023-10-01
IL260750A (https=) 2018-09-20
CN108699161A (zh) 2018-10-23
JP2023157927A (ja) 2023-10-26
WO2017149122A1 (en) 2017-09-08
KR20180118151A (ko) 2018-10-30
SG11201806214RA (en) 2018-08-30
CA3016098A1 (en) 2017-09-08
US11618789B2 (en) 2023-04-04
CN108699161B (zh) 2022-06-03
AU2017226960A1 (en) 2018-08-09
EP3423498A1 (en) 2019-01-09
US20230203189A1 (en) 2023-06-29
US20190077875A1 (en) 2019-03-14
IL305540B1 (en) 2024-05-01
IL305540B2 (en) 2024-09-01
JP7331168B2 (ja) 2023-08-22
AU2017226960B2 (en) 2024-03-21
US20240392034A1 (en) 2024-11-28
JP2019513346A (ja) 2019-05-30
IL305540A (en) 2023-10-01
JP2024169455A (ja) 2024-12-05
AU2024201503A1 (en) 2024-03-28
JP7557023B2 (ja) 2024-09-26
JP7362250B2 (ja) 2023-10-17
JP2022058881A (ja) 2022-04-12
KR102427948B1 (ko) 2022-08-02
JP7835815B2 (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
US20230203189A1 (en) Clinical assessment of m-protein response in multiple myeloma
CN111630068B (zh) 抗cd47抗体及其用途
JP7046973B2 (ja) 抗ｏｘ４０抗体およびその使用
JP2020508645A (ja) 抗ｃｄ４７抗体およびその使用
CN111094352A (zh) B7-h4抗体及其使用方法
AU2015265870A1 (en) PD-L1 antibodies and uses thereof
JP6661019B2 (ja) イヌ抗ｃｄ２０抗体
US12306183B2 (en) Immunofixation electrophoresis method with target component on-gel immunodisplacement
CA3016098C (en) Clinical assessment of m-protein response in multiple myeloma
JP2023510075A (ja) ヒト化抗ｃａ ｉｘ抗体、およびその使用方法
CN120441707B (zh) 结合特瑞普利单抗的抗体及其用途
HK1261804A1 (en) Clinical assessment of m-protein response in multiple myeloma
HK1261804B (en) Clinical assessment of m-protein response in multiple myeloma
HK40013319A (en) Anti-cd47 antibody and use thereof
HK40027698A (en) B7-h4 antibodies and methods of use thereof